Lessons from negative phase 3 trials in rheumatoid arthritis anno 2023
R Westhovens, P Verschueren - Annals of the Rheumatic Diseases, 2023 - ard.bmj.com
A recent phase 3 trial (contRAst 3) with otilimab, a drug targeting granulocytemacrophage
colony-stimulating factor (GM-CSF), was reported by Taylor et al to be negative in a …
colony-stimulating factor (GM-CSF), was reported by Taylor et al to be negative in a …